Journal article

SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission

Peter S Hamblin, Rosemary Wong, Elif Ekinci, Spiros Fourlanos, Sonali Shah, Alicia R Jones, Matthew JL Hare, Genevieve L Calder, Dilan Seneviratne Epa, Elizabeth M George, Rinky Giri, Mark A Kotowicz, Mervyn Kyi, Nicole Lafontaine, Richard J MacIsaac, Brendan J Nolan, David N O'Neal, Debra Renouf, Suresh Varadarajan, Jennifer Wong Show all

The Journal of Clinical Endocrinology & Metabolism | ENDOCRINE SOC | Published : 2019


CONTEXT: Diabetic ketoacidosis (DKA) has been associated with the use of sodium glucose cotransporter 2 inhibitors (SGLT2is). OBJECTIVE: To determine the incidence, characteristics, and outcomes of DKA in SGLT2i users vs nonusers with type 2 diabetes. DESIGN: Retrospective, multicenter, controlled cohort study. SETTING: All public hospitals in Melbourne and Geelong (combined population of 5 million), Australia, from 1 September 2015 to 31 October 2017. PATIENTS: Consecutive cases of DKA that developed in the community, or during the course of hospital admission, in patients with type 2 diabetes. MAIN OUTCOME MEASURES: In SGLT2i users vs nonusers: (i) OR of DKA developing during hospital admi..

View full abstract